In the CVOT, SUSTAIN 6, subcutaneous semaglutide was associated with a higher risk of diabetic retinopathy complications than placebo after 2.1 years ( 1c reduction in patients with pre-existing diabetic retinopathy ( Subcutaneous semaglutide significantly reduced the rate of MACE vs
Weight suppression in bulimia nervosa: Associations with biology and behavior
Creating a triple agonist was a major challenge
Another study demonstrated that compression (without cold) after injection of heparin had similar benefits
In addition to improving blood sugar control and promoting weight loss, semaglutide has also been shown to reduce the risk of major cardiovascular events, such as heart attack and stroke, in people with type 2 diabetes
As of April 2026, Rybelsus (oral semaglutide, Novo Nordisk) is the only FDA-approved oral GLP-1 receptor agonist